Trump Administration to Examine Ibogaine Drug Safety
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy CMND?
Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly.ORDER ON PSYCHEDELIC:A psychedelic used in some countries to treat post-traumatic stress disorder is expected to get a closer examination from the federal government on its safety and effectiveness, CBS News' Jennifer Jacobs and Celine Gounder, citing sources. The White House is drafting an executive order that would signal the Trump administration's willingness to further U.S. research into a drug called ibogaine, the authors add. Ibogaine, a naturally occurring compound from a shrub native to Africa, is used to treat depression, anxiety, addiction, post-traumatic stress disorder and brain trauma. Clearmind Medicine, AtaiBeckley, Cybin, Definium Therapeutics, GH Research, Compass Pathwaysand Psyence Biomedicalare trading higher following the news.STRAIT OF HORMUZ:Iran Foreign Minister Araghchi, "In line with the ceasefire in Lebanon, the passage for all commercial vessels through Strait of Hormuz is declared completely open for the remaining period of ceasefire, on the coordinated route as already announced by Ports and Maritime Organisation of the Islamic Rep. of Iran."In a post on Truth Social, President Trump, "THE STRAIT OF HORMUZ IS COMPLETELY OPEN AND READY FOR BUSINESS AND FULL PASSAGE, BUT THE NAVAL BLOCKADE WILL REMAIN IN FULL FORCE AND EFFECT AS IT PERTAINS TO IRAN, ONLY, UNTIL SUCH TIME AS OUR TRANSACTION WITH IRAN IS 100% COMPLETE. THIS PROCESS SHOULD GO VERY QUICKLY IN THAT MOST OF THE POINTS ARE ALREADY NEGOTIATED."ANTHROPIC MYTHOS AI:The U.S. government is preparing to make a version of Anthropic PBC's artificial intelligence model, Mythos, available to major federal agencies amid concerns it could increase cybersecurity risk, according to a memo reviewed by Bloomberg, Jake Bleiberg and Margi Murphy. The White House Office of Management and Budget is setting up protections to allow agencies to use Mythos, with more information to be provided "in the coming weeks," according to the report. Anthropic has limited the release of Mythos due to concerns that hackers could weaponize its capabilities to steal data or sabotage victim networks, and has briefed senior U.S. government officials on the model's capabilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CMND?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CMND
About CMND
Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Clearmind's Drug Clinical Trial Achieves Success
- Clinical Trial Success: Clearmind Medicine Inc.'s CMND-100 drug has met the primary safety and tolerability endpoints in its FDA-approved Phase I/IIa clinical trial, indicating promising prospects for treating Alcohol Use Disorder (AUD).
- Safety Data: Results from the third cohort show that CMND-100 exhibited a high safety profile even at higher doses, with no serious adverse events reported, further validating the drug's tolerability across different dosages.
- Multinational Study: The clinical trial is a multinational, multicenter study designed to evaluate the safety, tolerability, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD, supporting its potential as a novel non-hallucinogenic treatment option.
- Intellectual Property Strategy: Clearmind currently holds 19 patent families, including 31 granted patents, and plans to continue seeking additional patents to enhance its competitive position in the psychedelic drug market.
See More
Clearmind Medicine Reports Positive Clinical Trial Results and Regulatory Support
- Clinical Trial Milestone: Clearmind's CMND-100 successfully met its primary endpoint of safety and tolerability in the FDA-approved Phase I/IIa trial, with no serious adverse events observed in the highest dose tested, indicating significant potential as a non-hallucinogenic treatment for Alcohol Use Disorder.
- Regulatory Support: President Trump's Executive Order aims to accelerate psychedelic innovation and expand access to mental health care for veterans, which Clearmind describes as a historic step that reflects growing recognition of non-hallucinogenic neuroplastogens as potential therapies for conditions like PTSD and depression.
- Intellectual Property Expansion: Clearmind holds 19 patent families and 31 granted patents, with plans to further expand its intellectual property portfolio, demonstrating the company's commitment to ensuring breakthrough treatments reach patients responsibly and efficiently.
- Market Reaction: Following a 1-for-40 reverse stock split, CMND's stock price rose 58.42% to $1.14 during Monday's trading, although it fell 8.77% to $1.04 in overnight trading, reflecting positive market response to the company's developments alongside short-term volatility.
See More
Trump Signs Executive Order to Accelerate Psychedelic Research
- Funding Support: Trump signed an executive order allocating $50 million for psychedelic research aimed at accelerating studies on PTSD treatments, potentially paving the way for future drug reclassification.
- Clearmind Drug Progress: Clearmind Medicines' CMND-100 met its primary goal in early-stage trials, demonstrating strong safety with no serious side effects reported at higher doses, likely enhancing its market competitiveness.
- Market Reaction: Clearmind's shares surged nearly 65% in pre-market trading, marking its largest intraday gain since August 2022, reflecting strong investor interest in the therapeutic potential of psychedelics.
- Silo Pharma Development: Silo Pharma is developing SPC-15, a nasal spray designed to prevent PTSD, utilizing a fast nose-to-brain delivery method, and is expected to benefit from a more favorable regulatory environment.
See More
Trump Administration to Examine Safety of Psychedelic Drug for PTSD
- Psychedelic Research Advancement: The Trump administration is drafting an executive order indicating a willingness to further investigate the safety and efficacy of ibogaine, a psychedelic used for treating PTSD, which is expected to accelerate clinical research in this area.
- Positive Market Reaction: Following the announcement, stocks of companies like Clearmind Medicine (CMND), Atai Beckley (ATAI), and Cybin (HELP) rose, reflecting market optimism regarding the potential applications of psychedelics in mental health treatment.
- Strait of Hormuz Passage Statement: Iran's Foreign Minister declared that commercial vessels can fully pass through the Strait of Hormuz during the ceasefire in Lebanon, while Trump confirmed normal passage but maintained a naval blockade against Iran, highlighting the complexities of geopolitical tensions in the region.
- AI Model Utilization: The U.S. government is preparing to make Anthropic PBC's AI model Mythos available to major federal agencies despite cybersecurity risks, indicating a balancing act between promoting technological innovation and ensuring data security.
See More
Trump Administration to Examine Ibogaine Research for PTSD Funding
- Government Focus on Ibogaine: The Trump administration plans to closely examine ibogaine's safety and effectiveness, maintaining its Schedule I classification, which indicates a cautious approach to its potential medical applications.
- Research Funding Opening: President Trump is expected to sign an executive order aimed at unlocking federal funding for research into ibogaine's effectiveness for PTSD and traumatic brain injuries, particularly among veterans, signaling a significant policy shift.
- Stock Price Surge: Following the news, shares of Psyence Biomedical (PBM) surged over 141% on Thursday, potentially marking its best trading session, reflecting strong market confidence in the company's natural-derived therapies.
- Market Sentiment Extremely Bullish: On Stocktwits, retail sentiment around PBM stock remained in the 'extremely bullish' territory with message volume spiking, despite the stock having fallen approximately 95% over the past year.
See More
Clearmind Medicine's CMND-100 Trial Receives Positive DSMB Recommendation
- Clinical Trial Progress: Clearmind Medicine Inc.'s independent Data and Safety Monitoring Board has issued a positive recommendation for the ongoing FDA-approved Phase I/IIa clinical trial of CMND-100, indicating the drug's potential in treating Alcohol Use Disorder, particularly in light of limited effective treatment options.
- Positive Safety Data: Following the successful completion of the third patient cohort, top-line safety data for CMND-100 shows it was well tolerated with no serious adverse events reported, reinforcing the favorable safety profile observed in earlier cohorts.
- Dose Increase: As the trial advances to the fourth cohort, the tested dose of CMND-100 will increase to 160 mg, aimed at evaluating the drug's safety, tolerability, pharmacokinetics, and preliminary efficacy, demonstrating the company's confidence in its drug development.
- Stock Market Volatility: Despite a 28.57% drop in CMND's stock price to $0.65 during Wednesday's trading, the stock rebounded slightly to $0.66 in overnight trading, reflecting market interest and anticipation regarding the drug trial's progress.
See More
Clearmind's Drug Clinical Trial Achieves Success
- Clinical Trial Success: Clearmind Medicine Inc.'s CMND-100 drug has met the primary safety and tolerability endpoints in its FDA-approved Phase I/IIa clinical trial, indicating promising prospects for treating Alcohol Use Disorder (AUD).
- Safety Data: Results from the third cohort show that CMND-100 exhibited a high safety profile even at higher doses, with no serious adverse events reported, further validating the drug's tolerability across different dosages.
- Multinational Study: The clinical trial is a multinational, multicenter study designed to evaluate the safety, tolerability, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD, supporting its potential as a novel non-hallucinogenic treatment option.
- Intellectual Property Strategy: Clearmind currently holds 19 patent families, including 31 granted patents, and plans to continue seeking additional patents to enhance its competitive position in the psychedelic drug market.
See More
Clearmind Medicine Reports Positive Clinical Trial Results and Regulatory Support
- Clinical Trial Milestone: Clearmind's CMND-100 successfully met its primary endpoint of safety and tolerability in the FDA-approved Phase I/IIa trial, with no serious adverse events observed in the highest dose tested, indicating significant potential as a non-hallucinogenic treatment for Alcohol Use Disorder.
- Regulatory Support: President Trump's Executive Order aims to accelerate psychedelic innovation and expand access to mental health care for veterans, which Clearmind describes as a historic step that reflects growing recognition of non-hallucinogenic neuroplastogens as potential therapies for conditions like PTSD and depression.
- Intellectual Property Expansion: Clearmind holds 19 patent families and 31 granted patents, with plans to further expand its intellectual property portfolio, demonstrating the company's commitment to ensuring breakthrough treatments reach patients responsibly and efficiently.
- Market Reaction: Following a 1-for-40 reverse stock split, CMND's stock price rose 58.42% to $1.14 during Monday's trading, although it fell 8.77% to $1.04 in overnight trading, reflecting positive market response to the company's developments alongside short-term volatility.
See More
Trump Signs Executive Order to Accelerate Psychedelic Research
- Funding Support: Trump signed an executive order allocating $50 million for psychedelic research aimed at accelerating studies on PTSD treatments, potentially paving the way for future drug reclassification.
- Clearmind Drug Progress: Clearmind Medicines' CMND-100 met its primary goal in early-stage trials, demonstrating strong safety with no serious side effects reported at higher doses, likely enhancing its market competitiveness.
- Market Reaction: Clearmind's shares surged nearly 65% in pre-market trading, marking its largest intraday gain since August 2022, reflecting strong investor interest in the therapeutic potential of psychedelics.
- Silo Pharma Development: Silo Pharma is developing SPC-15, a nasal spray designed to prevent PTSD, utilizing a fast nose-to-brain delivery method, and is expected to benefit from a more favorable regulatory environment.
See More
Trump Administration to Examine Safety of Psychedelic Drug for PTSD
- Psychedelic Research Advancement: The Trump administration is drafting an executive order indicating a willingness to further investigate the safety and efficacy of ibogaine, a psychedelic used for treating PTSD, which is expected to accelerate clinical research in this area.
- Positive Market Reaction: Following the announcement, stocks of companies like Clearmind Medicine (CMND), Atai Beckley (ATAI), and Cybin (HELP) rose, reflecting market optimism regarding the potential applications of psychedelics in mental health treatment.
- Strait of Hormuz Passage Statement: Iran's Foreign Minister declared that commercial vessels can fully pass through the Strait of Hormuz during the ceasefire in Lebanon, while Trump confirmed normal passage but maintained a naval blockade against Iran, highlighting the complexities of geopolitical tensions in the region.
- AI Model Utilization: The U.S. government is preparing to make Anthropic PBC's AI model Mythos available to major federal agencies despite cybersecurity risks, indicating a balancing act between promoting technological innovation and ensuring data security.
See More
Trump Administration to Examine Ibogaine Research for PTSD Funding
- Government Focus on Ibogaine: The Trump administration plans to closely examine ibogaine's safety and effectiveness, maintaining its Schedule I classification, which indicates a cautious approach to its potential medical applications.
- Research Funding Opening: President Trump is expected to sign an executive order aimed at unlocking federal funding for research into ibogaine's effectiveness for PTSD and traumatic brain injuries, particularly among veterans, signaling a significant policy shift.
- Stock Price Surge: Following the news, shares of Psyence Biomedical (PBM) surged over 141% on Thursday, potentially marking its best trading session, reflecting strong market confidence in the company's natural-derived therapies.
- Market Sentiment Extremely Bullish: On Stocktwits, retail sentiment around PBM stock remained in the 'extremely bullish' territory with message volume spiking, despite the stock having fallen approximately 95% over the past year.
See More
Clearmind Medicine's CMND-100 Trial Receives Positive DSMB Recommendation
- Clinical Trial Progress: Clearmind Medicine Inc.'s independent Data and Safety Monitoring Board has issued a positive recommendation for the ongoing FDA-approved Phase I/IIa clinical trial of CMND-100, indicating the drug's potential in treating Alcohol Use Disorder, particularly in light of limited effective treatment options.
- Positive Safety Data: Following the successful completion of the third patient cohort, top-line safety data for CMND-100 shows it was well tolerated with no serious adverse events reported, reinforcing the favorable safety profile observed in earlier cohorts.
- Dose Increase: As the trial advances to the fourth cohort, the tested dose of CMND-100 will increase to 160 mg, aimed at evaluating the drug's safety, tolerability, pharmacokinetics, and preliminary efficacy, demonstrating the company's confidence in its drug development.
- Stock Market Volatility: Despite a 28.57% drop in CMND's stock price to $0.65 during Wednesday's trading, the stock rebounded slightly to $0.66 in overnight trading, reflecting market interest and anticipation regarding the drug trial's progress.
See More
